Compare DexCom, Inc. (DXCM) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Global X NASDAQ 100 Covered Call ETF — how do they compare? DexCom, Inc. trades at $77.63 (market cap $28.06B), while Global X NASDAQ 100 Covered Call ETF trades at $18.08. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | QYLD | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $89.53 | $18.52 |
52-Week Low | $54.84 | $16.46 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
QYLD trades at $18.05, down 1.74% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF's covered call strategy generates high dividend yields but has historically underperformed the Nasdaq-100's total returns. Recent articles highlight concerns about NAV erosion despite consistent monthly distributions.
The outlook remains mixed - QYLD offers attractive income for yield-seeking investors but faces structural limitations during strong market rallies. Key risks include capped upside potential and competition from lower-fee alternatives. Analyst sentiment is cautious due to long-term underperformance versus the broader index.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
